EXELExelixis, Inc.

Ticker: EXEL | Price: $55.32 | Today's Change: -3.67% Filing: 8-K (Item 8.01) | Filed with the SEC on: September 11, 2026

---

What Happened

Exelixis, Inc. filed an 8-K with the SEC on September 11, 2026 disclosing financial results for Q2 FY2026. The company reported revenue of approximately $1.12 billion (contract revenue excluding assessed tax), operating income of $400.4 million, and net income of $344.5 million for the quarter. Diluted earnings per share came in at $1.20, with basic EPS of $1.25.

---

Why It Matters

These are headline-level results that underscore the scale Exelixis has reached as a commercial-stage oncology company. A quarterly revenue run rate above $1.1 billion suggests the company's commercial portfolio — anchored by its cabozantinib franchise — is generating substantial and sustained cash flows. An operating margin implied by the reported figures (operating income of ~$400M on ~$1.12B in revenue) points to a mature, highly profitable core business. For investors, the key near-term question is whether this level of revenue and earnings is consistent with prior guidance or represents a beat or miss — that context is not provided in the structured filing data and would need to be drawn from accompanying earnings materials. The -3.67% move in the stock today may suggest the market had already priced in strong results, or that forward guidance or other commentary tempered enthusiasm — details not contained in the XBRL data provided.

---

Analysis

The Q2 FY2026 results reveal a company operating at a meaningfully different scale than the $727.5 million in revenues reported in Q3 FY2020 — also cited in the filing's XBRL data — underscoring the multi-year growth trajectory Exelixis has executed. The near-$1.13 billion quarterly revenue figure is a material milestone for a company whose commercial story has long centered on cabozantinib's expanding label across multiple tumor types.

The operating income of $400.4 million and net income of $344.5 million reflect strong conversion of revenue to profit, which warrants attention given ongoing pipeline investment costs typical of oncology-focused biotechs. What to watch next:

• Pipeline readouts: Whether management commentary accompanying this filing addresses late-stage pipeline catalysts, particularly any cabozantinib combination studies or next-generation assets.
• Revenue sustainability: Whether the $1.1B+ quarterly rate is driven by one-time milestones or royalties versus recurring product sales.
• Guidance revision: Any update to full-year 2026 financial guidance that may accompany this disclosure.

The stock's decline of -3.67% on the day of this report warrants monitoring — a negative reaction to strong absolute numbers often signals that investor expectations were set even higher, or that forward-looking commentary introduced new uncertainty.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure and is intended for informational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. No investment rating or price target is expressed or implied. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions. Financial figures cited are sourced directly from the filing's official XBRL data as provided.

Source

Filed with the SEC on 2026-09-11. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/exel-20260910.htm